The extract of Paris polyphylla exerts apoptotic induction and synergic antiproliferative effect with anticancer drugs in SMMC-7721 human liver cancer cells

Biomedicine and Preventive Nutrition

Volumn 1, Issue 3, 2011, Pages 186-194

  Sun, Jing ^a,b   Liu, Bao rui ^a,b   Wei, Jia ^a,b   Qian, Xiao ping ^a,b   Yu, Li xia ^a,b   Guo, Ren hua ^a,b   Shen, Hua ^a,b   Wang, Tong shan ^a,b   Shu, Yong qian ^a,b  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^b MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

Author keywords

Antineoplasic drugs; Apoptosis; Drug related genes; Paris polyphylla; Synergic effect

Indexed keywords

ALCOHOL; ANTINEOPLASTIC ALKALOID; DOCETAXEL; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FLUOROURACIL; MESSENGER RNA; OXALIPLATIN; PARIS POLYPHYLLA EXTRACT; PLANT EXTRACT; PROCASPASE 3; PROTEIN BAX; PROTEIN BCL 2; THYMIDYLATE SYNTHASE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE S PHASE; CELL DEATH; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG MECHANISM; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME REPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL CARCINOMA; MITOCHONDRIAL MEMBRANE POTENTIAL; PARIS POLYPHYLLA; PRIORITY JOURNAL; PROTEIN EXPRESSION; STAINING; TRANSMISSION ELECTRON MICROSCOPY; WESTERN BLOTTING;

EID: 83655182293     PISSN: 22105239     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bionut.2011.06.019     Document Type: Article

References (39)

1. Henry S.H., Bosch F.X., Bowers J.C. Aflatoxin, hepatitis and worldwide liver cancer risks. Adv Exp Med Biol 2002, 504:229-233.
2. Mann J. Natural products in cancer chemotherapy: past, present and future. Nat Rev Cancer 2002, 2:143-148.
3. Pharmacopoeia Commission of the Ministry of Public Health. The pharmacopoeia of People's Republic of China 2005:183.
4. Lee H., Lin J.Y. Antimutagenic activity of extracts from anticancer drugs in Chinese medicine. Mutat Res 1988, 204:229-234.
5. Matsuda H., Pongpiriyadacha Y., Morikawa T., Kishi A., Kataoka S., Yoshikawa M. Protective effects of steroid saponins from Paris polyphylla var yunnanensis. Bioorg Med Chem Lett 2003, 13:1101-1106.
6. Ghavami S, Hashemi M, Ande SR, Yeganeh B. Apoptosis and cancer: mutation within caspase genes. J Med Genet 2009; Jun 7 [epub ahead of print].
7. Burz C., Berindan-Neagoe I., Balacescu O., Irimie A. Apoptosis in cancer: Key molecular signaling pathways and therapy targets. Acta Oncol 2009, 9:1-11.
8. Lee W.S., Lee G.W., Kim H.W. A phase II trial of haptaplatin/5-FU and leucovorin for advanced stomach cancer. Cancer Res Treat 2005, 37:208-211.
9. Cassileth B.R. Alternative and complementary medicine. Cancer 1995, 86:1900-1902.
10. Yue P.Y., Mak N.K., Cheng Y.K., Leung K.W. Pharmacogenomics and the Yin/Yang actions of ginseng: anti-tumor, angiomodulating and steroid-like activities of ginsenosides. Chin Med 2007, 15:2-6.
11. Chou T.C., Talalay P. Quantitative analysis of doseeVect relationships: the combined eVects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984, 22:27-55.
12. McConkey D.J., Zhivotovsky B., Orrenius S. Apoptosis--molecular mechanisms and biomedical implications. Mol Aspects Med 1996, 1:101-110.
13. Urech K., Scher J.M., Hostanska K., Becker H. Apoptosis inducing activity of viscin, a lipophilic extract from Viscum album. J Pharm Pharmacol 2005, 57:101-109.
14. Kastan M.B., Bartek J. Cell-cycle checkpoints and cancer. Nature 2004, 432:316-323.
15. Dobashi Y. Cell cycle regulation and its aberrations in human lung carcinoma. Pathol Int 2005, 55:95-105.
16. Bartek J., Lukas C., Lukas J. Checking on DNA damage in S phase. Nat Rev Mol Cell Biol 2004, 5:792-804.
17. Ly J.D., Grubb D.R., Lawen A. The mitochondrial membrane potential (Ψm) in apoptosis: an update. Apoptosis 2003, 8:115-128.
18. Loeffler M., Kroemer G. The mitochondrion in cell death control: certainties and incognita. Exp Cell Res 2000, 25:619-626.
19. Nguyen M., Millar D.G., Yong V.W., Korsmeyer S.J., Shore G.C. Targeting of Bcl-2 to the mitochondrial outer membrane by a COOH-terminal signal anchor sequence. J Biol Chem 1993, 268:25265-25268.
20. Ghobrial I.M., Witzig T.E., Adjei A.A. Targeting apoptosis pathways in cancer therapy. CA Cancer J Clin 2005, 55:178-194.
21. Ashe P.C, Berry M.D. Apoptotic signaling cascades. Prog Neuropsychopharmacol Biol Psychiatry 2003, 27:199-214.
22. Porter A.G., Janicke R.U. Emerging roles of caspase-3 in apoptosis. Cell Death Differ 1999, 6:99-104.
23. Di Paolo A., Bocci G. Drug distribution in tumors: mechanisms, role in drug resistance, and methods for modification. Curr Oncol Rep 2007, 9:109-114.
24. Zhang X., Masakazu Y., Masaichi O. Synergic antiproliferative effect of DNA methyltransferase inhibitor in combination with anticancer drugs in gastric carcinoma. Cancer Sci 2006, 97:938-944.
25. Tendo M., Masakazu Y. A synergic inhibitory-effect of combination with selective cyclooxygenase-2 inhibitor and S-1 on the peritoneal metastasis for scirrhous gastric cancer cells. Cancer Lett 2006, 244:247-251.
26. Leichman C.G., Lenz H.-J., Leichman L., Danenberg K., Baranda J., Groshen S. Quantitation of intratumoral thymidilate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted infusion 5-fluorouracil and weekly leucovorin. J Clin Oncol 1997, 15:3223-3229.
27. Matsubara J., Nishina T., Yamada Y. Impacts of excision repair cross-complementing gene 1 (ERCC1), dihydropyrimidine dehydrogenase, and epidermal growth factor receptor on the outcomes of patients with advanced gastric cancer. Br J Cancer 2008, 98:832-839.
28. Yeh K.H., Shun C.T., Chen C.L. High expression of thymidylate synthase is associated with the drug resistance of gastric carcinoma to high dose 5-fluorouracil-based systemic chemotherapy. Cancer 1998, 82:1626-1631.
29. Santi D.V., McHenry C.S., Sommer H. Mechanism of interaction of thymidylate synthetase with 5-fluorodeoxyuridylate. Biochemistry 1974, 13:471-481.
30. Johnston P.G., Lenz H.J., Leichman C.G., Danenberg K.D., Allegra C.J., Danenberg P.V. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 1995, 55:1407-1412.
31. Edler D., Glimelius B., Hallstrom M., Jakobsen A., Johnston P.G., Magnusson I. Thymidylate synthase expression in colorectal cancer: a prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy. J Clin Oncol 2002, 20:1721-1728.
32. Quirino C.M. Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil. Oncology 2006, 70:366-377.
33. Laat W.L., Jaspers N.G., Hoeijmakers J.H. Molecular mechanism of nucleotide excision repair. Genes Dev 1999, 13:768-785.
34. Dabholkar M., Bostick-Bruton F., Weber C. ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients. J Natl Cancer Inst 1992, 84:1512-1517.
35. Dabholkar M., Bostick-Bruton F., Weber C. Expression of excision repair genes in non-malignant bone marrow from cancer patients. Mutat Res 1993, 293:151-160.
36. Dabholkar M.D., Berger M.S., Vionnet J.A. Malignant and nonmalignant brain tissues differ in theirmessenger RNA expression patterns for ERCC1 and ERCC2. Cancer Res 1995, 55:1261-1266.
37. Lee K.B., Parker R.J., Bohr V. Cisplatin sensitivity/resistance in UV repair-deficient Chinese hamster ovary cells of complementation groups 1 and 3. Carcinogenesis 1993, 14:2177-2180.
38. Scheeff E.D., Briggs J.M., Howell S.B. Molecular modeling of the intrastrand guanine-guanine DNA adducts produced by cisplatin and oxaliplatin. Mol Pharmacol 1999, 56:633-643.
39. Martin L.P., Hamilton T.C., Schilder R.J. Platinum resistance: the role of DNA repair pathways. Clin Cancer Res 2008, 14:1291-1295.